Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Wormser Freres Gestion

Wormser Freres Gestion boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,953 shares of the medical research company’s stock after acquiring an additional 222 shares during the period. Thermo Fisher Scientific accounts for 4.7% of Wormser Freres Gestion’s portfolio, making the stock its 9th largest position. Wormser Freres Gestion’s holdings in Thermo Fisher Scientific were worth $7,841,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Cypress Advisory Group LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $253,000. Intact Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock worth $1,353,000 after purchasing an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $1,121,000. Fifth Third Bancorp boosted its position in shares of Thermo Fisher Scientific by 11.6% during the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company’s stock worth $174,305,000 after purchasing an additional 34,917 shares in the last quarter. Finally, Independence Bank of Kentucky boosted its position in shares of Thermo Fisher Scientific by 21.0% during the fourth quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company’s stock worth $1,990,000 after purchasing an additional 663 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Citigroup reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Raymond James reaffirmed an “outperform” rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Finally, UBS Group cut their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $607.43.

Thermo Fisher Scientific Stock Down 1.7%

Thermo Fisher Scientific stock opened at $393.53 on Friday. The firm has a market capitalization of $148.56 billion, a PE ratio of 23.81, a P/E/G ratio of 2.99 and a beta of 0.82. The company’s 50-day moving average is $442.54 and its 200-day moving average is $505.23. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.11 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.